Results For "Parabilis-Medicines"

1 News Found

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

News | May 20, 2026

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform

Latest Stories

Boston Scientific invests $1.5 billion in MiRus for TAVR expansion

Amanta Healthcare reports 42% YoY growth in FY26 profit

Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Dr Vidya Veldore Vice President, Clinical Operations, 4baseCare

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

Dushyant Sapre Founder and CEO, SwishX

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Duraisamy Rajan Palani Founder and CEO, Archimedis Digital

Packaging